Atea Q4 2022 Earnings Report
Key Takeaways
Atea Pharmaceuticals reported its fourth quarter and full year 2022 financial results, highlighting progress in its clinical development programs, particularly for bemnifosbuvir in COVID-19 and HCV treatments. The company is focusing resources on COVID-19 and HCV programs, and has deprioritized the dengue program.
Patient enrollment continues in the Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19, with an interim analysis expected in 2H23.
A Phase 2 trial evaluating the combination of bemnifosbuvir and ruzasvir for HCV is expected to start enrollment in 2Q23, with initial results expected by 4Q23.
Atea has decided to deprioritize the dengue program to focus on COVID-19 and HCV programs.
Atea is advancing an internal program focused on the discovery of second-generation protease inhibitors for COVID-19 treatment.